HUP0104867A3 - Heterocyclic compounds useful in the treatment of inflammatory diseases, process for their preparation, pharmaceutical compositions comprising thereof and their use - Google Patents

Heterocyclic compounds useful in the treatment of inflammatory diseases, process for their preparation, pharmaceutical compositions comprising thereof and their use

Info

Publication number
HUP0104867A3
HUP0104867A3 HU0104867A HUP0104867A HUP0104867A3 HU P0104867 A3 HUP0104867 A3 HU P0104867A3 HU 0104867 A HU0104867 A HU 0104867A HU P0104867 A HUP0104867 A HU P0104867A HU P0104867 A3 HUP0104867 A3 HU P0104867A3
Authority
HU
Hungary
Prior art keywords
preparation
treatment
pharmaceutical compositions
inflammatory diseases
heterocyclic compounds
Prior art date
Application number
HU0104867A
Other languages
English (en)
Hungarian (hu)
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of HUP0104867A2 publication Critical patent/HUP0104867A2/hu
Publication of HUP0104867A3 publication Critical patent/HUP0104867A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/205—Radicals derived from carbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06043—Leu-amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HU0104867A 1998-12-18 1999-12-16 Heterocyclic compounds useful in the treatment of inflammatory diseases, process for their preparation, pharmaceutical compositions comprising thereof and their use HUP0104867A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9828074.6A GB9828074D0 (en) 1998-12-18 1998-12-18 Therapeutically useful compounds
PCT/EP1999/010000 WO2000037444A1 (en) 1998-12-18 1999-12-16 Compounds useful in the treatment of inflammatory diseases

Publications (2)

Publication Number Publication Date
HUP0104867A2 HUP0104867A2 (hu) 2002-04-29
HUP0104867A3 true HUP0104867A3 (en) 2002-06-28

Family

ID=10844608

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0104867A HUP0104867A3 (en) 1998-12-18 1999-12-16 Heterocyclic compounds useful in the treatment of inflammatory diseases, process for their preparation, pharmaceutical compositions comprising thereof and their use

Country Status (26)

Country Link
US (1) US6867192B1 (enExample)
EP (1) EP1140837B1 (enExample)
JP (1) JP4431282B2 (enExample)
KR (1) KR20010101258A (enExample)
CN (1) CN1330637A (enExample)
AR (1) AR023727A1 (enExample)
AT (1) ATE273954T1 (enExample)
AU (1) AU760169B2 (enExample)
BR (1) BR9916282A (enExample)
CA (1) CA2355630A1 (enExample)
CO (1) CO5170533A1 (enExample)
CZ (1) CZ20012209A3 (enExample)
DE (1) DE69919580T2 (enExample)
ES (1) ES2226488T3 (enExample)
GB (1) GB9828074D0 (enExample)
GT (1) GT199900217A (enExample)
HK (1) HK1038744A1 (enExample)
HU (1) HUP0104867A3 (enExample)
IL (1) IL142908A0 (enExample)
NO (1) NO20012995L (enExample)
NZ (1) NZ511478A (enExample)
PE (1) PE20001387A1 (enExample)
PL (1) PL348059A1 (enExample)
TR (1) TR200101709T2 (enExample)
WO (1) WO2000037444A1 (enExample)
ZA (1) ZA200103948B (enExample)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001051487A1 (en) 1999-12-28 2001-07-19 Pfizer Products Inc. Non-peptidyl inhibitors of vla-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases
GB0014881D0 (en) * 2000-06-16 2000-08-09 Glaxo Group Ltd Pharmaceutical aerosol formulation
GB0014869D0 (en) * 2000-06-16 2000-08-09 Glaxo Group Ltd Novel pharmaceutical formulation
GB0014892D0 (en) * 2000-06-16 2000-08-09 Glaxo Group Ltd Novel pharmaceutical formulation
GB0014947D0 (en) * 2000-06-16 2000-08-09 Glaxo Group Ltd Novel pharmaceutical formulation
GB0014851D0 (en) * 2000-06-16 2000-08-09 Glaxo Group Ltd Novel pharmaceutical formulation
GB0014849D0 (en) * 2000-06-16 2000-08-09 Glaxo Group Ltd Pharmaceutical aerosol formulation
GB0014883D0 (en) * 2000-06-16 2000-08-09 Glaxo Group Ltd Novel pharmaceutical formulation
GB0127423D0 (en) * 2001-11-15 2002-01-09 Glaxo Group Ltd Process
GB0218630D0 (en) 2002-08-10 2002-09-18 Tanabe Seiyaku Co Novel compounds
WO2004103967A2 (en) 2003-05-20 2004-12-02 Genentech, Inc. Thiocarbamate inhibitors of alpha-4 integrins
KR20070029733A (ko) 2004-06-04 2007-03-14 제넨테크, 인크. 다발성 경화증의 치료 방법
US8310442B2 (en) 2005-02-23 2012-11-13 Pixtronix, Inc. Circuits for controlling display apparatus
US9261694B2 (en) 2005-02-23 2016-02-16 Pixtronix, Inc. Display apparatus and methods for manufacture thereof
US7999994B2 (en) 2005-02-23 2011-08-16 Pixtronix, Inc. Display apparatus and methods for manufacture thereof
US8159428B2 (en) 2005-02-23 2012-04-17 Pixtronix, Inc. Display methods and apparatus
US20070205969A1 (en) 2005-02-23 2007-09-06 Pixtronix, Incorporated Direct-view MEMS display devices and methods for generating images thereon
US9158106B2 (en) 2005-02-23 2015-10-13 Pixtronix, Inc. Display methods and apparatus
US8519945B2 (en) 2006-01-06 2013-08-27 Pixtronix, Inc. Circuits for controlling display apparatus
US9229222B2 (en) 2005-02-23 2016-01-05 Pixtronix, Inc. Alignment methods in fluid-filled MEMS displays
US8482496B2 (en) 2006-01-06 2013-07-09 Pixtronix, Inc. Circuits for controlling MEMS display apparatus on a transparent substrate
US7742016B2 (en) 2005-02-23 2010-06-22 Pixtronix, Incorporated Display methods and apparatus
US9082353B2 (en) 2010-01-05 2015-07-14 Pixtronix, Inc. Circuits for controlling display apparatus
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
US8526096B2 (en) 2006-02-23 2013-09-03 Pixtronix, Inc. Mechanical light modulators with stressed beams
US9176318B2 (en) * 2007-05-18 2015-11-03 Pixtronix, Inc. Methods for manufacturing fluid-filled MEMS displays
TW201438738A (zh) 2008-09-16 2014-10-16 Genentech Inc 治療進展型多發性硬化症之方法
US8169679B2 (en) 2008-10-27 2012-05-01 Pixtronix, Inc. MEMS anchors
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
KR101659642B1 (ko) 2010-02-02 2016-09-26 픽스트로닉스 인코포레이티드 디스플레이 장치를 제어하기 위한 회로
WO2011097252A2 (en) 2010-02-02 2011-08-11 Pixtronix, Inc. Methods for manufacturing cold seal fluid-filled display apparatus
WO2013101771A2 (en) 2011-12-30 2013-07-04 Genentech, Inc. Compositions and method for treating autoimmune diseases
AR091305A1 (es) 2012-01-31 2015-01-28 Genentech Inc ANTICUERPOS ANTI-IgE Y SUS METODOS DE USO
US9134552B2 (en) 2013-03-13 2015-09-15 Pixtronix, Inc. Display apparatus with narrow gap electrostatic actuators
WO2015181837A2 (en) * 2014-05-30 2015-12-03 Sphaera Pharma Pvt. Ltd. Novel compounds as anti-tubercular agents
PL3319639T3 (pl) * 2015-07-08 2021-03-08 Axerovision, Inc. Kompozycje farmaceutyczne zawierające antagonistę integryny alfa4 do stosowania w leczeniu stanów zapalnych oka
HRP20250052T1 (hr) 2015-10-06 2025-03-14 F. Hoffmann - La Roche Ag Postupak liječenja multiple skleroze
HRP20220479T1 (hr) * 2016-06-01 2022-05-27 Athira Pharma, Inc. Spojevi
CN109722455B (zh) * 2017-10-31 2022-03-11 中国科学院天津工业生物技术研究所 微生物发酵生产谷内酯的方法、工程菌及应用
WO2019246455A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
ES3003232T3 (en) 2018-10-30 2025-03-10 Gilead Sciences Inc Compounds for inhibition of alpha4beta7 integrin
ES2987796T3 (es) 2018-10-30 2024-11-18 Gilead Sciences Inc Derivados de N-benzoil-fenilalanina como inhibidores de la integrina alfa4beta7 para el tratamiento de enfermedades inflamatorias
CN112969687B (zh) 2018-10-30 2024-08-23 吉利德科学公司 作为α4β7整合素抑制剂的喹啉衍生物
CA3114240C (en) 2018-10-30 2023-09-05 Gilead Sciences, Inc. Imidazopyridine derivatives as alpha4beta7 integrin inhibitors
CN114222730B (zh) 2019-08-14 2024-09-10 吉利德科学公司 用于抑制α4β7整合素的化合物
JP2023546915A (ja) * 2020-10-21 2023-11-08 アズーラ オフサルミックス エルティーディー． 眼障害を処置するための化合物および方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1593858A1 (de) 1967-03-02 1970-10-29 Hoechst Ag Verfahren zur Herstellung tyrosinhaltiger Peptide und deren Derivaten
US4105602A (en) 1975-02-10 1978-08-08 Armour Pharmaceutical Company Synthesis of peptides with parathyroid hormone activity
US6248713B1 (en) 1995-07-11 2001-06-19 Biogen, Inc. Cell adhesion inhibitors
AU728435B2 (en) 1997-05-29 2001-01-11 Merck & Co., Inc. Sulfonamides as cell adhesion inhibitors
ES2257808T3 (es) 1997-05-29 2006-08-01 MERCK & CO., INC. (A NEW JERSEY CORP.) Acidos biarilalcanoicos como inhibidores de adhesion celular.
CA2291778A1 (en) 1997-05-29 1998-12-03 Merck & Co., Inc. Heterocyclic amide compounds as cell adhesion inhibitors
ATE256699T1 (de) * 1997-05-30 2004-01-15 Celltech Therapeutics Ltd Entzündungshemmende tyrosin-derivate

Also Published As

Publication number Publication date
ATE273954T1 (de) 2004-09-15
US6867192B1 (en) 2005-03-15
ES2226488T3 (es) 2005-03-16
PL348059A1 (en) 2002-05-06
CZ20012209A3 (cs) 2001-09-12
GT199900217A (es) 2001-06-09
HUP0104867A2 (hu) 2002-04-29
GB9828074D0 (en) 1999-02-17
NO20012995D0 (no) 2001-06-15
PE20001387A1 (es) 2000-12-22
EP1140837B1 (en) 2004-08-18
BR9916282A (pt) 2001-10-02
JP4431282B2 (ja) 2010-03-10
CA2355630A1 (en) 2000-06-29
AR023727A1 (es) 2002-09-04
IL142908A0 (en) 2002-04-21
AU3039100A (en) 2000-07-12
EP1140837A1 (en) 2001-10-10
WO2000037444A1 (en) 2000-06-29
CO5170533A1 (es) 2002-06-27
NO20012995L (no) 2001-08-15
TR200101709T2 (tr) 2001-12-21
JP2002533326A (ja) 2002-10-08
HK1038744A1 (zh) 2002-03-28
AU760169B2 (en) 2003-05-08
CN1330637A (zh) 2002-01-09
ZA200103948B (en) 2002-11-15
NZ511478A (en) 2003-08-29
DE69919580T2 (de) 2005-09-01
DE69919580D1 (de) 2004-09-23
KR20010101258A (ko) 2001-11-14

Similar Documents

Publication Publication Date Title
HUP0104867A3 (en) Heterocyclic compounds useful in the treatment of inflammatory diseases, process for their preparation, pharmaceutical compositions comprising thereof and their use
HUP0301101A3 (en) Novel heterocyclic compounds process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
ZA975866B (en) Novel heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases.
HUP0102556A3 (en) Benzenesulfonamide-derivatives and their use as medicaments and process for the preparation of the compounds
IL147217A0 (en) New spirooxindole derivatives and pharmaceutical compositions containing the same for treatment of pain
HUP0204399A3 (en) Pteridine compounds for the treatment of psoriasis, process for their preparation, pharmaceutical compositions containing them and their use
HUP0303296A3 (en) Carboxamide derivatives and their use in the treatment of thromboembolic diseases and tumours, process for their preparation and pharmaceutical compositions containing them
HUP0203542A3 (en) 3(5)-amino-pyrazole derivatives, process for their preparation, their use and pharmaceutical compositions containing the same
HUP0203142A3 (en) Benzodiazepine derivatives, process for preparation of the compounds, pharmaceutical compositions containing them and their use
HUP0400918A3 (en) Utilization of pyrazoline derivatives in the preparation of pharmaceutical compositions for the prevention and/or treatment of proliferative cell diseases
HUP0301167A3 (en) Sulfonyl-pyrrolidine derivatives useful for the treatment of neurological disorders, process for their preparation, pharmaceutical compositions containing them and their use
HUP0204226A3 (en) Quinazoline derivatives, pharmaceutical compositions containing them, their use and process for the preparation of the compounds
HUP0004120A3 (en) Use of cgmp-pde5 inhibitors for the preparation of pharmaceutical compositions treating neuropathy
IL122733A0 (en) Pharmaceutical compositions for use in the treatment of allergic asthma
HUP0105313A3 (en) Potassium salt of (s)-omeprazole, process for its preparation and pharmaceutical composition containing the same and its use
HUP0200553A3 (en) Use of pyridine derivatives as mglur5 antagonists producing pharmaceutical compositions suitable for the treatment of pain and anxiety
AP2000002010A0 (en) Novel pharmaceutical compositions for treating and saving and the methods for the preparation thereof
HUP0200441A3 (en) Tetrahydropyran derivatives and their use as therapeutic agents and process for preparation the compounds
HUP0203597A3 (en) Pharmaceutical compositions containing zolmitriptan, process for their preparation and their use
HUP0104963A3 (en) Compositions for the treatment of skin diseases
HUP9904027A3 (en) Use of p-aminophenol derivatives for the preparation of pharmaceutical compositions useful in the treatment of neurodegenerative diseases
IL155174A0 (en) Methods and compositions for the treatment of inflammatory diseases
HUP0401325A3 (en) Isoxazolopyridinones useful in the treatment of parkinson's disease, process for their preparation and pharmaceutical compositions containing the compounds
HUP0300402A3 (en) Quinolinyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment of pain and pharmaceutical compositions containing them
GC0000335A (en) Compositions formed of polyolefins, process for their preparation and use of these compositions